Table 3.

Summary of studies for locally advanced pancreatic cancer

Study	Year	Chemo	Radiation	No. of patients	Resection rate, %	Borderline	Borderline resection rate	Median survival unresected	Median survival resected (borderline)
Weese et al32	1990	5-FU, MIT	50.4	15	67			7
Jessup et al29	1993	5-FU	>45	16	13			8	20
Yeung et al120	1993	5-FU, MIT	50.4	26	38			8
Kamthan et al121	1997	5-FU, CDDP, STZ	54	35	14			15	31
White et al122	1999	5-FU, MIT or CDDP	45	25	20			10
Bajetta et al123	1999	5-FU, Leu	50	32	16			10 overall
Wanebo et al124	2000	5-FU, CDDP	45	14	64 (3 refused)			9	19
Kim et al125	2002	5-FU/GEM		87	1 (n = 1)			11	18
Rau et al126	2002	5-FU, CDDP	45	26	42			10
Crane et al114	2002	5-FU or GEM	30	114	2 vs 9			9 vs 10
Aristu et al127	2003	5-FU or CDDP	45	47	19			10	23
Ammori et al28	2003	GEM	39.6	6 7	13	18	33%	12	18
Wilkowski et al128	2004	GEM, CDDP	45–50	47	42 (R0 27)			11	24 (for R0)
Sa Cunha et al129	2005	5-FU, CDDP	45	61	21			11	28
Delpero130	2006	5-FU, CDDP	45	26	58			21	Not reached
Adhoute et al131	2006	5-FU CDDP	45–50.4	33	24			16
Massuco et al33	2006	GEM	45	28	29%			10	721
Marti et al41	2007	GEM, CDDP		26	15	3	100%	13	(12–62)
Budiharto et al113	2008	GEM	45 or 54	5 vs 6	60 vs 33			20
Brown et al34	2008	Various 5-FU, cap/bev, or GEM	50.4			13	100		(69% OS at 2 yrs)
Chauffert et al42	2008	5-FU/CDDP + GEM	60 Gy	59
Tinkl et al132	2009	GEM, CDDP or 5-FU, MIT	3D55.8	120	32			25	52 (for R0)
Small et al38	2008	GEM	36	9.14	33%		7%*	3	33%

Notes:

^*One patient deemed unresectable underwent surgery after neoadjuvant treatment.

Abbreviations: 5-FU, fluorouracil; CDDP, cisplatin; GEM, gemcitabine; cap/bev, capecitabine/bevacizumab; MIT, mitomycin C treatment.